Oncobiologics, Inc. (NASDAQ:OTLK – Free Report) – Stock analysts at HC Wainwright increased their Q3 2026 earnings estimates for Oncobiologics in a research report issued to clients and investors on Monday, July 27th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.05) for the quarter, up from their previous estimate of ($0.07). HC Wainwright currently has a “Neutral” rating and a $1.60 target price on the stock. The consensus estimate for Oncobiologics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Oncobiologics’ Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.47) EPS, Q1 2027 earnings at ($0.01) EPS, Q2 2027 earnings at ($0.01) EPS, Q3 2027 earnings at ($0.01) EPS, Q4 2027 earnings at $0.00 EPS, FY2027 earnings at ($0.03) EPS, FY2028 earnings at $0.09 EPS, FY2029 earnings at $0.15 EPS and FY2030 earnings at $0.32 EPS.
A number of other research firms also recently issued reports on OTLK. Wall Street Zen downgraded shares of Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Ascendiant Capital Markets lifted their price target on shares of Oncobiologics from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, June 11th. BTIG Research upgraded shares of Oncobiologics from a “neutral” rating to a “buy” rating and set a $4.00 price objective on the stock in a report on Monday. Finally, Weiss Ratings raised shares of Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $4.65.
Oncobiologics Stock Down 15.1%
Shares of OTLK stock opened at $0.90 on Wednesday. The firm has a 50 day moving average of $1.21 and a 200-day moving average of $0.66. The company has a market cap of $134.33 million, a price-to-earnings ratio of -0.77 and a beta of 0.77. Oncobiologics has a 52 week low of $0.16 and a 52 week high of $3.39.
Oncobiologics (NASDAQ:OTLK – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The business had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $4.39 million.
Insider Buying and Selling
In related news, Director Ghiath M. Sukhtian acquired 8,539,709 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were acquired at an average cost of $0.59 per share, for a total transaction of $5,038,428.31. Following the purchase, the director owned 22,092,068 shares in the company, valued at approximately $13,034,320.12. The trade was a 63.01% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.80% of the company’s stock.
Hedge Funds Weigh In On Oncobiologics
Hedge funds and other institutional investors have recently modified their holdings of the business. AQR Capital Management LLC increased its position in shares of Oncobiologics by 42.7% during the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after acquiring an additional 25,351 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares during the period. Hedge funds and other institutional investors own 11.20% of the company’s stock.
About Oncobiologics
Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.
Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.
Featured Stories
- Five stocks we like better than Oncobiologics
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.
